Introduction: This study aimed to assess the effectiveness of fractional exhaled nitric oxide (FeNO) combined with pulmonary function testing (PFT) for predicting the treatment outcome of patients with severe asthma receiving dupilumab. Methods: A total of 31 patients with severe asthma visiting our hospital from January 2022 to June 2023 were included in this study, with 28 patients completing a 16-week course of dupilumab treatment. Baseline clinical data, including demographic information, blood eosinophil counts, serum IgE levels, FeNO, asthma control test (ACT), asthma control questionnaire (ACQ), and other parameters, were collected. A predictive model using a generalized linear model was established. Results: Following the 16-week course of dupilumab treatment, 22 patients showed effective response based on GETE scores, while 6 patients were nonresponders. Notably, significant improvements were observed in clinical parameters such as blood eosinophil counts, serum IgE levels, FeNO, FEV1, FEV1%, ACT, and ACQ in both response groups (p < 0.05). FeNO and pulmonary function tests demonstrated AUC values of 0.530, 0.561, and 0.765, respectively, in predicting the clinical efficacy of dupilumab, which were lower than when FeNO was combined with FEV1%. The combination of FeNO and FEV1% had a sensitivity of 1.000 and specificity of 0.591 in predicting treatment response. Conclusion: The combined assessment of FeNO and FEV1% provides improved accuracy for predicting the clinical efficacy of dupilumab in managing severe asthma. However, further larger scale clinical studies with comprehensive follow-up data are needed to validate the therapeutic efficacy and applicability across diverse patient populations.

1.
Nagase
H
,
Suzukawa
M
,
Oishi
K
,
Matsunaga
K
.
Biologics for severe asthma: the real-world evidence, effectiveness of switching, and prediction factors for the efficacy
.
Allergol Int
.
2023
;
72
(
1
):
11
23
.
2.
Porsbjerg
C
,
Melén
E
,
Lehtimäki
L
,
Shaw
D
.
Asthma
.
Lancet
.
2023
;
401
(
10379
):
858
73
.
3.
Mosnaim
G
.
Asthma in adults
.
N Engl J Med
.
2023
;
389
(
11
):
1023
31
.
4.
Shin
YH
,
Hwang
J
,
Kwon
R
,
Lee
SW
,
Kim
MS
;
GBD 2019 Allergic Disorders Collaborators
,
Shin
JI
, et al
.
Global, regional, and national burden of allergic disorders and their risk factors in 204 countries and territories, from 1990 to 2019: a systematic analysis for the Global Burden of Disease Study 2019
.
Allergy
.
2023
;
78
(
8
):
2232
54
.
5.
Reddel
HK
,
Bacharier
LB
,
Bateman
ED
,
Brightling
CE
,
Brusselle
GG
,
Buhl
R
, et al
.
Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes
.
Eur Respir J
.
2022
;
59
(
1
):
2102730
.
6.
Agache
I
,
Eguiluz-Gracia
I
,
Cojanu
C
,
Laculiceanu
A
,
Del Giacco
S
,
Zemelka-Wiacek
M
, et al
.
Advances and highlights in asthma in 2021
.
Allergy
.
2021
;
76
(
11
):
3390
407
.
7.
Aegerter
H
,
Lambrecht
BN
.
The pathology of asthma: what is obstructing our view
.
Annu Rev Pathol
.
2023
;
18
:
387
409
.
8.
Rupani
H
,
Kent
BD
.
Using fractional exhaled nitric oxide measurement in clinical asthma management
.
Chest
.
2022
;
161
(
4
):
906
17
.
9.
Schoos
AM
,
Christiansen
CF
,
Stokholm
J
,
Bønnelykke
K
,
Bisgaard
H
,
Chawes
BL
.
FeNO and exercise testing in children at risk of asthma
.
J Allergy Clin Immunol Pract
.
2018
;
6
(
3
):
855
62.e2
.
10.
Corren
J
,
Pham
TH
,
Garcia Gil
E
,
Sałapa
K
,
Ren
P
,
Parnes
JR
, et al
.
Baseline type 2 biomarker levels and response to tezepelumab in severe asthma
.
Allergy
.
2022
;
77
(
6
):
1786
96
.
11.
Harb
H
,
Chatila
TA
.
Mechanisms of dupilumab
.
Clin Exp Allergy
.
2020
;
50
(
1
):
5
14
.
12.
Alsaffar
RM
,
Alkholifi
FK
.
Exploring the efficacy and contribution of Dupilumab in asthma management
.
Mol Immunol
.
2022
;
146
:
9
17
.
13.
Crimi
C
,
Campisi
R
,
Noto
A
,
Genco
S
,
Cacopardo
G
,
Nolasco
S
, et al
.
Comparability of asthma control test scores between self and physician-administered test
.
Respir Med
.
2020
;
170
:
106015
.
14.
Jovicic
N
,
Petrovic
M
,
Radovic
I
,
Lazovic
B
,
Soldatovic
I
.
Validation of online version of asthma control questionnaire in pediatric patients
.
J Asthma
.
2023
;
60
(
8
):
1553
7
.
15.
Panettieri
RA
Jr
,
Chipps
BE
,
Moore
WC
,
Soong
W
,
Carr
WW
,
Kreindler
JL
, et al
.
Differing perceptions of asthma control and treatment effectiveness by patients with severe asthma and treating subspecialists in the United States
.
J Asthma
.
2022
;
59
(
9
):
1859
68
.
16.
Lee
SW
.
Methods for testing statistical differences between groups in medical research: statistical standard and guideline of Life Cycle Committee
.
Life Cycle
.
2022
;
2
:
e1
.
17.
Wechsler
ME
,
Ford
LB
,
Maspero
JF
,
Pavord
ID
,
Papi
A
,
Bourdin
A
, et al
.
Long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma (TRAVERSE): an open-label extension study
.
Lancet Respir Med
.
2022
;
10
(
1
):
11
25
.
18.
Sockrider
M
,
Fussner
L
.
What is asthma
.
Am J Respir Crit Care Med
.
2020
;
202
(
9
):
P25
p26
.
19.
Reddel
HK
,
Bacharier
LB
,
Bateman
ED
,
Brightling
CE
,
Brusselle
GG
,
Buhl
R
, et al
.
Global initiative for asthma strategy 2021: executive summary and rationale for key changes
.
Am J Respir Crit Care Med
.
2022
;
205
(
1
):
17
35
.
20.
Chiu
CJ
,
Huang
MT
.
Asthma in the precision medicine era: biologics and probiotics
.
Int J Mol Sci
.
2021
;
22
(
9
):
4528
.
21.
Thomas
D
,
McDonald
VM
,
Pavord
ID
,
Gibson
PG
.
Asthma remission: what is it and how can it be achieved
.
Eur Respir J
.
2022
;
60
(
5
):
2102583
.
22.
Jenkins
CR
,
Boulet
LP
,
Lavoie
KL
,
Raherison-Semjen
C
,
Singh
D
.
Personalized treatment of asthma: the importance of sex and gender differences
.
J Allergy Clin Immunol Pract
.
2022
;
10
(
4
):
963
71.e3
.
23.
Al Heialy
S
,
Ramakrishnan
RK
,
Hamid
Q
.
Recent advances in the immunopathogenesis of severe asthma
.
J Allergy Clin Immunol
.
2022
;
149
(
2
):
455
65
.
24.
Ramsahai
JM
,
Hansbro
PM
,
Wark
PAB
.
Mechanisms and management of asthma exacerbations
.
Am J Respir Crit Care Med
.
2019
;
199
(
4
):
423
32
.
25.
Liu
B
,
Song
X
,
Liao
S
,
Luan
T
,
Zhao
Z
.
Comparison of efficacy of baricitinib and dupilumab in the treatment of Chinese moderate-to-severe atopic dermatitis: a retrospective study
.
Int Arch Allergy Immunol
.
2023
;
184
(
10
):
966
74
.
26.
Akenroye
A
,
Lassiter
G
,
Jackson
JW
,
Keet
C
,
Segal
J
,
Alexander
GC
, et al
.
Comparative efficacy of mepolizumab, benralizumab, and dupilumab in eosinophilic asthma: a Bayesian network meta-analysis
.
J Allergy Clin Immunol
.
2022
;
150
(
5
):
1097
105.e12
.
27.
Bacharier
LB
,
Maspero
JF
,
Katelaris
CH
,
Fiocchi
AG
,
Gagnon
R
,
de Mir
I
, et al
.
Dupilumab in children with uncontrolled moderate-to-severe asthma
.
N Engl J Med
.
2021
;
385
(
24
):
2230
40
.
28.
Pavord
ID
,
Deniz
Y
,
Corren
J
,
Casale
TB
,
FitzGerald
JM
,
Izuhara
K
, et al
.
Baseline FeNO independently predicts the dupilumab response in patients with moderate-to-severe asthma
.
J Allergy Clin Immunol Pract
.
2023
;
11
(
4
):
1213
20.e2
.
29.
Cakmak
ME
,
Öztop
N
,
Yeğit
OO
.
Comparison of the general characteristics of patients with severe asthma who switched from omalizumab to mepolizumab versus patients who responded to omalizumab treatment: a real-life study
.
Int Arch Allergy Immunol
.
2024
;
185
(
2
):
158
66
.
You do not currently have access to this content.